Karyopharm Therapeutics Inc. (30) | Uncategorized (12)

Recent Contracts

Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on May 3, 2021)
Offer Letter, dated as of April 28, 2021, between the Company and Richard Paulson (Filed With SEC on May 3, 2021)
Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on May 3, 2021)
Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 24, 2021)
Letter Agreement, dated as of October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on November 2, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on August 31, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on August 31, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Christopher B. Primiano (Filed With SEC on August 31, 2020)
Letter Agreement, dated as of August 31, 2020, between the Company and Michael Mason (Filed With SEC on August 31, 2020)
Amendment No. 1 to the Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated May 5, 2020 (Filed With SEC on May 5, 2020)
Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 26, 2020)
Offer Letter, dated February 3, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)